BioCentury
ARTICLE | Emerging Company Profile

Beactica: More Efficient Resonance

June 22, 2009 7:00 AM UTC

Surface plasmon resonance, or SPR, is used in fragment-based drug discovery because it provides a wealth of information about how a compound or fragment interacts with its target. Beactica AB is seeking to improve the interpretation of that information, and subsequently the optimization of leads, with an add-on to GE Healthcare's Biacore SPR discovery platform.

The newco initially will perform contract research to generate revenues it can use to advance its own pipeline of small molecules...